1 Thai AA,Solomon BJ,Sequist LV,et al.Lung cancer[J].Lancet,2021,398(10299):535-554. 2 Reck M,Remon J,Hellmann MD.First-Line immunotherapy for non-small-cell lung ancer[J].J Clin Oncol,2022,40(6):586-597. 3 Borghaei H,Gettinger S,Vokes EE,et al.Five-year outcomes from the randomized,phase iii trials checkmate 017 and 057:nivolumab versus docetaxel in previously treated non-small-cell lung cancer[J].J Clin Oncol,2021,39(7):723-733. 4 Xu C,Chen YP,Du XJ,et al.Comparative safety of immune checkpoint inhibitors in cancer:systematic review and network meta-analysis[J].BMJ,2018,363:k4226. 5 Russo A,Franchina T,Ricciardi GRR,et al.Baseline neutrophilia,derived neutrophil-to-lymphocyte ratio(dNLR),platelet-to-lymphocyte ratio(PLR),and outcome in non small cell lung cancer(NSCLC)treated with Nivolumab or Docetaxel[J].J Cell Physiol,2018,233(10):6337-6343. 6 Mezquita L,Auclin E,Ferrara R,et al.Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J].JAMA Oncol,2018,4(3):351-357. 7 Shaul ME,Fridlender ZG.Tumour-associated neutrophils in patients with cancer[J].Nat Rev Clin Oncol,2019,16(10):601-620. 8 Haemmerle M,Stone RL,Menter DG,et al.The platelet lifeline to cancer:challenges and opportunities[J].Cancer Cell,2018,33(6):965-983. 9 Chen DS,Mellman I.Oncology meets immunology:the cancer-immunity cycle[J].Immunity,2013,39(1):1-10. 10 Ding J,Karp JE,Emadi A.Elevated lactate dehydrogenase(LDH)can be a marker of immune suppression in cancer:interplay between hematologic and solid neoplastic clones and their microenvironments[J].Cancer Biomark,2017,19(4):353-363. 11 Haanen J,Carbonnel F,Robert C,et al.Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):264-266. 12 Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247. 13 Khoja L,Day D,Wei-Wu Chen T,et al.Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors:a systematic review[J].Ann Oncol,2017,28(10):2377-2385. 14 Peravali M,Gomes-Lima C,Tefera E,et al.Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses[J].World J Clin Oncol,2021,12(2):103-114. 15 Pavan A,Calvetti L,Dal Maso A,et al.Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors[J].Oncologist,2019,24(8):1128-1136. 16 Eun Y,Kim IY,Sun JM,et al.Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab[J].Sci Rep,2019,9(1):14039. 17 Capone M,Giannarelli D,Mallardo D,et al.Baseline neutrophil-to-lymphocyte ratio(NLR)and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab[J].J Immunother Cancer,2018,6(1):74. 18 Guida M,Bartolomeo N,Quaresmini D,et al.Basal and one-month differed neutrophil,lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma[J].J Transl Med,2022,20(1):159. |